Bispecific May Be New Standard of Care for Certain NSCLC, HARMONi-6 Data at ESMO 2025 Suggest

1 month ago 44

In patients with squamous NSCLC, ivonescimab plus chemotherapy was associated with a PFS benefit compared with tislelizumab (Tevimbra) plus chemotherapy.

1. Homepage
2. Lung Cancer
3. Bispecific May Be New Standard of Care for Certain NSCLC, HARMONi-6 Data at ESMO 2025 Suggest